MX2019008621A - Peptidos terapeuticos y neuroprotectores. - Google Patents

Peptidos terapeuticos y neuroprotectores.

Info

Publication number
MX2019008621A
MX2019008621A MX2019008621A MX2019008621A MX2019008621A MX 2019008621 A MX2019008621 A MX 2019008621A MX 2019008621 A MX2019008621 A MX 2019008621A MX 2019008621 A MX2019008621 A MX 2019008621A MX 2019008621 A MX2019008621 A MX 2019008621A
Authority
MX
Mexico
Prior art keywords
retinal
treating
inherited
therapeutic
enhancing
Prior art date
Application number
MX2019008621A
Other languages
English (en)
Inventor
L Karageozian Hampar
Y Park John
H Karageozian Vicken
Original Assignee
Allegro Pharmaceuticals Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allegro Pharmaceuticals Llc filed Critical Allegro Pharmaceuticals Llc
Publication of MX2019008621A publication Critical patent/MX2019008621A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Los péptidos no naturales y sus métodos de uso en seres humanos o animales no humanos pueden causar un efecto tal como: neuroprotección, protección contra o disminución de alteración o daños en los nervios, tratamiento del glaucoma, tratamiento de la degeneración macular relacionada con la edad u otras degeneraciones retinianas hereditarias o adquiridas, mejora de la reparación del tejido retiniano, mejora de la terapia regenerativa de la retina a través de la activación de células inmunes innatas o el tratamiento de la degeneración retiniana hereditaria o adquirida.
MX2019008621A 2017-01-19 2018-01-18 Peptidos terapeuticos y neuroprotectores. MX2019008621A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762448300P 2017-01-19 2017-01-19
US201762500998P 2017-05-03 2017-05-03
PCT/US2018/014287 WO2018136669A2 (en) 2017-01-19 2018-01-18 Therapeutic and neuroprotective peptides

Publications (1)

Publication Number Publication Date
MX2019008621A true MX2019008621A (es) 2020-01-21

Family

ID=62905452

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019008621A MX2019008621A (es) 2017-01-19 2018-01-18 Peptidos terapeuticos y neuroprotectores.

Country Status (12)

Country Link
US (2) US20180207227A1 (es)
EP (1) EP3570867A4 (es)
JP (1) JP7330510B2 (es)
KR (1) KR20190120197A (es)
CN (1) CN110678193A (es)
AU (1) AU2018210241A1 (es)
BR (1) BR112019014843A2 (es)
CA (1) CA3050904A1 (es)
IL (1) IL268169A (es)
MX (1) MX2019008621A (es)
WO (1) WO2018136669A2 (es)
ZA (1) ZA201905372B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110559422A (zh) 2009-11-10 2019-12-13 急速制药公司 用于抑制细胞粘附至rgd结合位点或引导诊断剂或治疗剂至 rgd结合位点的方法
US11673914B2 (en) 2009-11-10 2023-06-13 Allegro Pharmaceuticals, LLC Peptide therapies for reduction of macular thickening
EP3642219A4 (en) * 2017-06-19 2021-06-09 Allegro Pharmaceuticals, LLC PEPTIDE COMPOSITIONS AND RELATED PROCEDURES
KR20220054598A (ko) * 2019-07-26 2022-05-03 알레그로 파마슈티칼스, 엘엘씨 비삼출성 황반변성 및 기타 안질환 치료용 펩티드
CN115605215A (zh) * 2020-03-06 2023-01-13 急速制药有限责任公司（Us） 改善或减轻线粒体功能损伤的治疗

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6194415B1 (en) * 1995-06-28 2001-02-27 Allergan Sales, Inc. Method of using (2-imidazolin-2-ylamino) quinoxoalines in treating neural injury
US7510824B2 (en) * 1999-06-02 2009-03-31 Nono Inc. Method of screening peptides useful in treating traumatic injury to the brain or spinal cord
WO2004060265A2 (en) * 2003-01-07 2004-07-22 Yeda Research And Development Co. Ltd. Eye-drop vaccine containing copolymer 1 for therapeutic immunization
CN110559422A (zh) 2009-11-10 2019-12-13 急速制药公司 用于抑制细胞粘附至rgd结合位点或引导诊断剂或治疗剂至 rgd结合位点的方法
US11673914B2 (en) * 2009-11-10 2023-06-13 Allegro Pharmaceuticals, LLC Peptide therapies for reduction of macular thickening
RU2721907C2 (ru) * 2011-05-09 2020-05-25 Аллегро Фармасьютикалс, Инк. Антагонисты интегриновых рецепторов и их применение
WO2017170626A1 (ja) 2016-03-30 2017-10-05 千寿製薬株式会社 水性液剤
EP3642219A4 (en) * 2017-06-19 2021-06-09 Allegro Pharmaceuticals, LLC PEPTIDE COMPOSITIONS AND RELATED PROCEDURES
KR20220054598A (ko) * 2019-07-26 2022-05-03 알레그로 파마슈티칼스, 엘엘씨 비삼출성 황반변성 및 기타 안질환 치료용 펩티드

Also Published As

Publication number Publication date
ZA201905372B (en) 2021-01-27
BR112019014843A2 (pt) 2020-04-14
EP3570867A4 (en) 2020-12-23
RU2019126014A (ru) 2021-02-19
AU2018210241A1 (en) 2019-08-22
IL268169A (en) 2019-09-26
EP3570867A2 (en) 2019-11-27
JP7330510B2 (ja) 2023-08-22
RU2019126014A3 (es) 2021-02-19
WO2018136669A3 (en) 2018-09-27
US20210085749A1 (en) 2021-03-25
WO2018136669A2 (en) 2018-07-26
CN110678193A (zh) 2020-01-10
KR20190120197A (ko) 2019-10-23
US20180207227A1 (en) 2018-07-26
WO2018136669A8 (en) 2019-12-26
CA3050904A1 (en) 2018-07-26
JP2020505365A (ja) 2020-02-20

Similar Documents

Publication Publication Date Title
MX2019008621A (es) Peptidos terapeuticos y neuroprotectores.
IL272105A (en) Local administration of pharmaceutical agents containing cell-penetrating peptides for use in the treatment of age-related macular degeneration and other eye diseases
WO2020047462A3 (en) Methods of treating aging-related disorders
MX2017005204A (es) Dispositivos y métodos de estimulación para tratar el ojo seco.
MX2021013837A (es) Enfoque de inmunoterapias de combinacion para el tratamiento del cancer.
PH12017501217A1 (en) Methods of treating retinal diseases
MX2017015938A (es) Inhibidores de ezh2 para el tratar linfomas.
NZ704579A (en) Nasal stimulation devices and methods
PH12019500892A1 (en) Treating gastric cancer using combination therapies comprising liposomal irinotecan, oxaliplatin, 5-fluoruracil (and leucovorin)
MX2022000754A (es) Composiciones y metodos de uso de nintedanib para tratar enfermedades oculares con neovascularizacion anormal.
MX2018005313A (es) Vesiculas extracelulares de las celulas neurales.
BR112016019432A8 (pt) composição terapêutica, kit e seus usos na terapia gênica contra degeneração da retina
MX2018004616A (es) Cosmetica qie tiene bacterias probioticas.
MX2016009306A (es) Reequilibrado inmunologico epicutaneo.
MY196991A (en) Anti-cd154 antibody having improved binding, functional and safety characteristics and use in human immunotherapy
MX2020008680A (es) Terapia de combinacion con apilimod y agentes glutamatergicos.
MX2018008645A (es) Derivados de 8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano.
PH12017501993A1 (en) Methods of treating epstein-barr-virus-associated lymphoproliferative disorders by t cell therapy
PH12018502161A1 (en) Methods of treatment for cholestatic and fibrotic diseases
WO2018132828A3 (en) Uvb light therapy for immune disorders
PH12017500392A1 (en) Medical treatments based on anamorelin
MX2022005063A (es) Tratamiento de enfermedades oculares con antagonistas de receptor de endotelina.
MX2016016090A (es) Composicion oftalmica para el tratamiento de infeccion ocular.
TN2019000112A1 (en) Ophthalmic formulation comprising citicoline carried by liposome for the treatment of glaucoma
MX2018010223A (es) Terapia combinada para tratamiento de cancer de ovario.